AKER Akers Biosciences Inc gains 22% Feb 19, 2021

Akers Biosciences, Inc., together with its subsidiaries, focuses on the development and sale of disposable diagnostic testing devices to facilitate time sensitive therapeutic decisions in the United States and internationally. The company offers BreathScan/CHUBE, a disposable breath alcohol detector; BreathScan PRO, a quantitative breath alcohol detection system; METRON, a disposable breath ketone device to monitor weight loss; VIVO for the measurement of biological markers for oxidative stress that relates to cellular damage non-invasively; PIFA Heparin/PF4 and PIFA PLUSS PF4 rapid assay for detecting heparin-induced thrombocytopenia antibodies; seraSTAT, a device to separate rapid blood cells; and Tri-Cholesterol Check' to estimate high density lipoprotein cholesterol and low density lipo protein levels. It is also involved in the development of Breath Ketone Check', a disposable breath ketone device for diabetic monitoring, and management of senile dementia and alzheimers disease patients; Breath PulmoHealth Check', a suite of breath tests for biomarkers indicating asthma, chronic obstructive pulmonary disease, and lung cancer; and PIFA PLUSS that provides rapid tests for various infectious diseases. The company was founded in 1989 and is headquartered in Thorofare, New Jersey.http://www.priceseries.com/trade/AKER-Akers-Biosciences-Inc-stock-gains-22-percent-a-Trade-Record-by-priceSeries-2021020420210219.html